Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 3/20 | 0.41 |
| ▸ | ABCB1 | P08183 | 3/20 | 0.41 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.41 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.41 |
| ▸ | TLR7 | Q9NYK1 | 3/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | PI4KA | P42356 | 1/20 | 0.39 |
| ▸ | PI4K2B | Q8TCG2 | 1/20 | 0.39 |
| ▸ | PI4K2A | Q9BTU6 | 1/20 | 0.39 |
| ▸ | PI4KB | Q9UBF8 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | KDM1A | O60341 | 1/20 | 0.38 |
| ▸ | HTR2A | P28223 | 1/20 | 0.38 |
| ▸ | HTR2C | P28335 | 1/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.37 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.37 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.37 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5164682 | 0.95 | ABCB1 (0.45) | MAPTABCB1ADORA1ADORA2ATLR7 | |
| SCHEMBL5177679 | 0.91 | PI4KA (0.46) | MAPTABCB1ADORA1ADORA2ATLR7 | |
| SCHEMBL5162427 | 0.86 | ABCB1 (0.48) | MAPTABCB1ADORA1ADORA2ATLR7 | |
| SCHEMBL5159098 | 0.83 | TLR7 (0.52) | TLR7CYP1A2CYP2C9CYP2C19CYP2D6 | |
| SCHEMBL5356672 | 0.81 | ADORA2A (0.54) | ADORA1ADORA2ATLR7ALDH1A1CYP1A2 | |
| SCHEMBL5163699 | 0.79 | ADORA1 (0.56) | MAPTADORA1ADORA2ATLR7ALDH1A1 | |
| SCHEMBL5161101 | 0.77 | ADORA1 (0.50) | MAPTABCB1ADORA1ADORA2AGAA | |
| SCHEMBL5160809 | 0.76 | ADORA2A (0.48) | MAPTABCB1ADORA1ADORA2AALDH1A1 | |
| SCHEMBL5161088 | 0.75 | ALDH1A1 (0.42) | MAPTADORA1ADORA2AGAAHTT | |
| SCHEMBL5163016 | 0.74 | KDM4E (0.57) | MAPTADORA1ADORA2AGAAHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7189730-B2 | A2A adenosine receptor antagonists | CV THERAPEUTICS, INC. (US) | 2007-03-13 | — | — | US | disclosed |
| EP-1456209-B1 | A2A ADENOSINE RECEPTOR ANTAGONISTS | CV THERAPEUTICS INC (US) | 2007-02-28 | — | — | EP | disclosed |
| US-20030149060-A1 | A2A adenosine receptor antagonists | CV THERAPEUTICS, INC. | 2003-08-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030149060-A1 | A2A adenosine receptor antagonists | ADORA2A, ADORA2B, ADORA3 | MAPT 3794/4885ABCB1 1206/4885ADORA1 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.